Rhumbline Advisers Purchases 7,525 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Rhumbline Advisers grew its position in shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 23.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 39,656 shares of the company’s stock after purchasing an additional 7,525 shares during the quarter. Rhumbline Advisers owned about 0.13% of Actinium Pharmaceuticals worth $293,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its holdings in Actinium Pharmaceuticals by 28.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after purchasing an additional 19,035 shares during the last quarter. Virtu Financial LLC raised its holdings in Actinium Pharmaceuticals by 319.2% during the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock worth $642,000 after purchasing an additional 62,459 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Actinium Pharmaceuticals by 6.0% in the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after acquiring an additional 82,113 shares in the last quarter. Finally, Sanders Morris Harris LLC bought a new stake in shares of Actinium Pharmaceuticals in the 1st quarter valued at $78,000. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Stock Up 0.6 %

Shares of ATNM stock opened at $1.80 on Friday. The company has a market cap of $53.60 million, a price-to-earnings ratio of -1.05 and a beta of 0.14. The company’s fifty day simple moving average is $3.06. Actinium Pharmaceuticals, Inc. has a 12 month low of $1.33 and a 12 month high of $10.24.

Actinium Pharmaceuticals (NYSE:ATNM) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. Research analysts anticipate that Actinium Pharmaceuticals, Inc. will post -1.38 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on ATNM shares. Maxim Group lowered their price objective on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. HC Wainwright lowered their price objective on shares of Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, September 18th. Finally, B. Riley lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $16.00 to $2.00 in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.40.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).